Literature DB >> 9679975

Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes.

T van Hall1, N E van de Rhee, S P Schoenberger, M P Vierboom, F A Verreck, C J Melief, R Offringa.   

Abstract

Murine tumor cells obtained through transfection of expression plasmids carrying activated cellular and/or viral oncogenes constitute formidable tools for immunological tumor research. As reported previously, mouse embryo cells of C57BL/6 origin, transformed by mutated p53 or human papilloma virus type 16 (HPV16), present, at their surface, MHC-bound peptides that are derived from the p53 and the HPV16 E7 oncoproteins, respectively, which can serve as a target for a highly effective antitumor T-cell response. Here, we describe the identification, through molecular cloning, of an additional, highly immunodominant peptide that is presented by the aforementioned HPV16- and p53-transformed cells. This peptide is encoded by a cryptic open reading frame in the backbone sequences of the plasmids that had been used to generate these cells. Considerable amounts of transcripts encompassing this open reading frame were detected in the cells concerned. These transcripts were the result of the bidirectional nature of the retroviral long terminal repeat (LTR) present in the expression plasmids used for transfection, which resulted in transcription of the gene of interest, as well as in transcription of the vector sequences positioned at the other side of the LTR. Due to this mechanism, all tumor cells harboring LTR-driven expression plasmids expressed the highly immunogenic peptide, whereas cells containing plasmids driven by more unidirectional promoters exhibited lower levels of this peptide. LTR-driven expression plasmids were also shown to encode this peptide epitope when used for DNA vaccination, as mice vaccinated with such a plasmid developed a CTL response against this peptide. Our data show that awareness of plasmid backbone-derived epitopes is of crucial importance for the correct interpretation of preclinical experiments and for the design of DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679975

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

2.  Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.

Authors:  Shreya Kanodia; Diane M Da Silva; Tigran Karamanukyan; Lies Bogaert; Yang-Xin Fu; W Martin Kast
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

3.  Self-Induced Back-Action Actuated Nanopore Electrophoresis (SANE) Sensor for Label-Free Detection of Cancer Immunotherapy-Relevant Antibody-Ligand Interactions.

Authors:  Sai Santosh Sasank Peri; Muhammad Usman Raza; Manoj K Sabnani; Soroush Ghaffari; Susanne Gimlin; Debra D Wawro; Jung Soo Lee; Min Jun Kim; Jon Weidanz; George Alexandrakis
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

Review 5.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

6.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

Authors:  Moniek A de Witte; Gavin M Bendle; Marly D van den Boom; Miriam Coccoris; Todd D Schell; Satvir S Tevethia; Harm van Tinteren; Elly M Mesman; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

7.  Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection.

Authors:  Elena N Klyushnenkova; Diana V Kouiavskaia; Carla A Berard; Richard B Alexander
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

8.  A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Authors:  Elena N Klyushnenkova; Diana V Kouiavskaia; Christopher J Parkins; Patrizia Caposio; Sara Botto; Richard B Alexander; Michael A Jarvis
Journal:  J Immunother       Date:  2012-06       Impact factor: 4.456

9.  Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response.

Authors:  Joseph G Skeate; Diane M Da Silva; Elena Chavez-Juan; Snjezana Anand; Richard Nuccitelli; W Martin Kast
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

10.  Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.

Authors:  J M Luke; J M Vincent; S X Du; U Gerdemann; A M Leen; R G Whalen; C P Hodgson; J A Williams
Journal:  Gene Ther       Date:  2010-11-25       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.